Background: Compounds previously studied as anticancer were screened against
trypomastigotes to access the bioactivity. The epimastigote form of Trypanosoma cruzi Y strain and
the promastigote form of Leishmania amazonensis and Leishmania infantum were used in this work.
Methods: Cell-based assays were performed to access the bioactivity of the compounds using MTT
and the flow cytometry methods.
Results: Neq0438, Neq0474 and Neq0440 had the highest potency, with EC50 of 39 μM (L.
amazonensis), 52 μM (T. cruzi) and 81 μM (T. cruzi), respectively. These molecules were inactive
for Balb/C fibroblast cell line at concentrations above 250 μM, showing selectivity for the parasites.
Conclusion: This is the first report that demonstrates antiparasitic activity for the 2-aminopyridine
scaffold, with cross-activity against cancer cells.